QUANTITATIVE IMPROVEMENTS OF HIGH RESOLUTION PET USING A HIGH RESOLUTION RESEARCH TOMOGRAPH (HRRT) IN COMPARISON WITH A CLINICAL PET CAMERA: A STUDY IN NORMAL SUBJECTS USING THE TRACERS [11C]RACLOPRIDE, [11C]FLUMAZENIL AND [11C]Verapamil.

QUANTITATIVE IMPROVEMENTS OF HIGH RESOLUTION PET USING A HIGH RESOLUTION RESEARCH TOMOGRAPH (HRRT) IN COMPARISON WITH A CLINICAL PET CAMERA: A STUDY IN NORMAL SUBJECTS USING THE TRACERS [11C]RACLOPRIDE, [11C]FLUMAZENIL AND [11C]Verapamil. - Quantification using a high resolution research tomograph PET scanner

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31527

Enrollment

Registered

2006-08-11

Start date

2006-01-05

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurological and psychiatric diseases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age between 25 and 70 years good physical health RDC diagnosis never mentally ill BMI between 20-25 scores on Mini mental state examination (MMSE) >

Exclusion criteria

Exclusion criteria: · Any clinical significant abnormality of any clinical laboratory test, including drug screening. · Any subject who received any investigational medication within 30 days prior to the start of the study or who is scheduled to receive an investigational drug. · Any major current psychiatric diagnosis on axis-1 of DSM-IV · History of psychiatric or neurological illness · History of psychiatric or neurological illness in first-degree relatives · History of alcohol and/or drug abuse (DSM-IV criteria) · Current use of any medication

Design outcomes

Primary

Measure	Time frame
Data sets obtained with both scanners will be used to derive quantitative PET pharmacokinetic parameters such volume of distribution and binding potential. These parameters provide quantitative information about binding of the administered tracer to the neuroreceptor or about the distribution of neuroreceptor density. These parameters can be determined at a regional level using the volumes of interest approach. However, also parametric kinetic methods will be applied to both datasets in order to derive 3D volumetric images representing the distribution of the PET pharmacokinetic parameters across the entire brain at best possible resolution. Parametric analysis will thus provide quantitative information with highest spatial detail. Consequently, it will allow most accurate evaluation of PET quantification improvements with the high resolution PET camera. Finally, by reducing the resolution of the HRRT scans to that of the clinical HR+ scanner (smoothing) it is possible to determine whether observed differences in binding potential or volume of distribution are caused by differences in resolution alone or if improvements of image reconstruction algorithms or acquisition parameters are still required.	—

Measure

Time frame

Data sets obtained with both scanners will be used to derive quantitative PET pharmacokinetic parameters such volume of distribution and binding potential. These parameters provide quantitative information about binding of the administered tracer to the neuroreceptor or about the distribution of neuroreceptor density. These parameters can be determined at a regional level using the volumes of interest approach. However, also parametric kinetic methods will be applied to both datasets in order to derive 3D volumetric images representing the distribution of the PET pharmacokinetic parameters across the entire brain at best possible resolution. Parametric analysis will thus provide quantitative information with highest spatial detail. Consequently, it will allow most accurate evaluation of PET quantification improvements with the high resolution PET camera. Finally, by reducing the resolution of the HRRT scans to that of the clinical HR+ scanner (smoothing) it is possible to determine whether observed differences in binding potential or volume of distribution are caused by differences in resolution alone or if improvements of image reconstruction algorithms or acquisition parameters are still required.

—

Secondary

Measure	Time frame
Determination of the quantitative accuracy of the HRRT PET scanner	—

Countries

Netherlands

Outcome results